Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 5/20 | 0.62 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.59 |
| ▸ | GSK3B | P49841 | 4/20 | 0.59 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.59 |
| ▸ | CDC7 | O00311 | 3/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.59 |
| ▸ | PIM1 | P11309 | 3/20 | 0.59 |
| ▸ | PRKACA | P17612 | 3/20 | 0.59 |
| ▸ | GSK3A | P49840 | 3/20 | 0.59 |
| ▸ | PLK1 | P53350 | 2/20 | 0.59 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.59 |
| ▸ | JAK2 | O60674 | 2/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.59 |
| ▸ | PAK4 | O96013 | 2/20 | 0.59 |
| ▸ | CDK2 | P24941 | 2/20 | 0.59 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.59 |
| ▸ | CLK2 | P49760 | 2/20 | 0.59 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.59 |
| ▸ | STK3 | Q13188 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3811561 | 0.89 | PIN1 (0.67) | PIN1MAPK9GSK3BMAPK8CDC7 | |
| SCHEMBL3814860 | 0.88 | PIN1 (0.62) | PIN1MAPK9GSK3BMAPK8CDC7 | |
| SCHEMBL2062751 | 0.86 | PIN1 (0.59) | PIN1MAPK9GSK3BMAPK8CDC7 | |
| SCHEMBL3808780 | 0.86 | PLK1 (0.64) | PIN1MAPK9GSK3BMAPK8CDC7 | |
| SCHEMBL3807294 | 0.86 | PIN1 (0.59) | PIN1MAPK9GSK3BMAPK8CDC7 | |
| SCHEMBL3812655 | 0.84 | PIN1 (0.57) | PIN1MAPK9GSK3BMAPK8CDC7 | |
| SCHEMBL13577830 | 0.84 | MAPK9 (0.68) | MAPK9GSK3BMAPK8CDC7ROCK2 | |
| SCHEMBL1202555 | 0.82 | MAPK10 (0.68) | MAPK9GSK3BMAPK8CDC7ROCK2 | |
| SCHEMBL6193458 | 0.82 | PIN1 (0.54) | PIN1MAPK9GSK3BMAPK8CDC7 | |
| SCHEMBL17194046 | 0.81 | MAPK10 (0.52) | MAPK9GSK3BMAPK8CDC7ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884098-B2 | 2-{[5-Fluoro-2-({3-[2-(4-morpholinyl)ethyl]phenyl}amino)-4-pyrimidinyl]amino}-N-(2-hydroxyethyl)benzamide, useful in the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-02-08 | — | — | US | disclosed |
| US-20100016318-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-21 | — | — | US | disclosed |
| US-7625903-B2 | Anticancer agent; N-(1-methylethyl)-2-[(5-methyl-2-{[3-(4-methyl-2-oxo-1-piperazinyl)phenyl]amino}-4-pyrimidinyl)amino]benzamide | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-01 | — | — | US | disclosed |
| EP-2121637-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | Smithkline Beecham Corporation (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-1597251-B1 | PYRIMIDINE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-06-10 | — | — | EP | disclosed |
| US-7514446-B2 | Pyrimidine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514446-B2 | Pyrimidine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514446-B2 | Pyrimidine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080182852-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | GLAXOSMITHKLINE LLC | 2008-07-31 | — | — | US | disclosed |
| WO-2008092049-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-31 | — | — | WO | disclosed |
| US-20070010668-A1 | Pyrimidine compounds | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-01-11 | — | — | US | disclosed |
| US-20070010668-A1 | Pyrimidine compounds | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-01-11 | — | — | US | disclosed |
| US-20070010668-A1 | Pyrimidine compounds | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-01-11 | — | — | US | disclosed |
| EP-1597251-A2 | PYRIMIDINE COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004074244-A2 | PYRIMIDINE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182852-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | AURKA, AURKC, AURKB | PIN1 2467/4885MAPK9 348/4885GSK3B 324/4885 |
| US-20070010668-A1 | Pyrimidine compounds | TYMS, TYMP, DPYD | PIN1 1535/4885MAPK9 1837/4885GSK3B 2540/4885 |
| US-20100016318-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | AURKA, AURKC, AURKB | PIN1 2645/4885MAPK9 303/4885GSK3B 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.